Literature DB >> 22058220

Telomere length is associated with disease severity and declines with age in dyskeratosis congenita.

Blanche P Alter1, Philip S Rosenberg, Neelam Giri, Gabriela M Baerlocher, Peter M Lansdorp, Sharon A Savage.   

Abstract

BACKGROUND: Dyskeratosis congenita is a cancer-prone bone marrow failure syndrome caused by aberrations in telomere biology. DESIGN AND METHODS: We studied 65 patients with dyskeratosis congenita and 127 unaffected relatives. Telomere length was measured by automated multicolor flow fluorescence in situ hybridization in peripheral blood leukocyte subsets. We age-adjusted telomere length using Z-scores (standard deviations from the mean for age).
RESULTS: We confirmed that telomere lengths below the first percentile for age are very sensitive and specific for the diagnosis of dyskeratosis congenita. We provide evidence that lymphocytes alone and not granulocytes may suffice for clinical screening, while lymphocyte subsets may be required for challenging cases, including identification of silent carriers. We show for the first time using flow fluorescence in situ hybridization that the shortest telomeres are associated with severe variants (Hoyeraal-Hreidarsson and Revesz syndromes), mutations in DKC1, TINF2, or unknown genes, and moderate or severe aplastic anemia. In the first longitudinal follow up of dyskeratosis congenita patients, we demonstrate that telomere lengths decline with age, in contrast to the apparent stable telomere length observed in cross-sectional data.
CONCLUSIONS: Telomere length by flow fluorescence in situ hybridization is an important diagnostic test for dyskeratosis congenita; age-adjusted values provide a quantitative measure of disease severity (clinical subset, mutated gene, and degree of bone marrow failure). Patients with dyskeratosis congenita have accelerated telomere shortening. This study is registered at www.clinicaltrials.gov (identifier: NCT00027274).

Entities:  

Mesh:

Year:  2011        PMID: 22058220      PMCID: PMC3291588          DOI: 10.3324/haematol.2011.055269

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  18 in total

Review 1.  Dyskeratosis congenita in all its forms.

Authors:  I Dokal
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

2.  Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation.

Authors:  Tom J Vulliamy; Anna Marrone; Stuart W Knight; Amanda Walne; Philip J Mason; Inderjeet Dokal
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

3.  Flow cytometry and FISH to measure the average length of telomeres (flow FISH).

Authors:  Gabriela M Baerlocher; Irma Vulto; Gary de Jong; Peter M Lansdorp
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

4.  Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality.

Authors:  B M Camitta; E D Thomas; D G Nathan; G Santos; E C Gordon-Smith; R P Gale; J M Rappeport; R Storb
Journal:  Blood       Date:  1976-07       Impact factor: 22.113

5.  Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA.

Authors:  Patrick F Fogarty; Hiroki Yamaguchi; Adrian Wiestner; Gabriela M Baerlocher; Elaine Sloand; Weihua S Zeng; Elizabeth J Read; Peter M Lansdorp; Neal S Young
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

6.  Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita.

Authors:  Blanche P Alter; Gabriela M Baerlocher; Sharon A Savage; Stephen J Chanock; Babette B Weksler; Judith P Willner; June A Peters; Neelam Giri; Peter M Lansdorp
Journal:  Blood       Date:  2007-04-27       Impact factor: 22.113

Review 7.  Telomeres and aging.

Authors:  Geraldine Aubert; Peter M Lansdorp
Journal:  Physiol Rev       Date:  2008-04       Impact factor: 37.312

8.  Short telomeres are a risk factor for idiopathic pulmonary fibrosis.

Authors:  Jonathan K Alder; Julian J-L Chen; Lisa Lancaster; Sonye Danoff; Shu-chih Su; Joy D Cogan; Irma Vulto; Mingyi Xie; Xiaodong Qi; Rubin M Tuder; John A Phillips; Peter M Lansdorp; James E Loyd; Mary Y Armanios
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

9.  TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita.

Authors:  Sharon A Savage; Neelam Giri; Gabriela M Baerlocher; Nick Orr; Peter M Lansdorp; Blanche P Alter
Journal:  Am J Hum Genet       Date:  2008-01-31       Impact factor: 11.025

10.  Telomere length measurement can distinguish pathogenic from non-pathogenic variants in the shelterin component, TIN2.

Authors:  T Vulliamy; R Beswick; M J Kirwan; U Hossain; A J Walne; I Dokal
Journal:  Clin Genet       Date:  2011-01-04       Impact factor: 4.438

View more
  94 in total

Review 1.  The molecular genetics of the telomere biology disorders.

Authors:  Alison A Bertuch
Journal:  RNA Biol       Date:  2015-09-23       Impact factor: 4.652

Review 2.  Understanding telomere diseases through analysis of patient-derived iPS cells.

Authors:  Luis F Z Batista; Steven E Artandi
Journal:  Curr Opin Genet Dev       Date:  2013-08-28       Impact factor: 5.578

3.  Telomere length varies by DNA extraction method: implications for epidemiologic research.

Authors:  Julie M Cunningham; Ruth A Johnson; Kristin Litzelman; Halcyon G Skinner; Songwon Seo; Corinne D Engelman; Russell J Vanderboom; Grace W Kimmel; Ronald E Gangnon; Douglas L Riegert-Johnson; John A Baron; John D Potter; Robert Haile; Daniel D Buchanan; Mark A Jenkins; David N Rider; Stephen N Thibodeau; Gloria M Petersen; Lisa A Boardman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-09-09       Impact factor: 4.254

4.  Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita.

Authors:  Payal P Khincha; Alison A Bertuch; Shahinaz M Gadalla; Neelam Giri; Blanche P Alter; Sharon A Savage
Journal:  Blood Adv       Date:  2018-06-12

5.  Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.

Authors:  Robert B Gerbing; Todd A Alonzo; Lillian Sung; Alan S Gamis; Soheil Meshinchi; Sharon E Plon; Alison A Bertuch; Maria M Gramatges
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

Review 6.  Extrahematopoietic manifestations of the short telomere syndromes.

Authors:  Kristen E Schratz
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

7.  Germline mutations of regulator of telomere elongation helicase 1, RTEL1, in Dyskeratosis congenita.

Authors:  Bari J Ballew; Meredith Yeager; Kevin Jacobs; Neelam Giri; Joseph Boland; Laurie Burdett; Blanche P Alter; Sharon A Savage
Journal:  Hum Genet       Date:  2013-01-18       Impact factor: 4.132

8.  Investigation of chromosome X inactivation and clinical phenotypes in female carriers of DKC1 mutations.

Authors:  Jialin Xu; Payal P Khincha; Neelam Giri; Blanche P Alter; Sharon A Savage; Judy M Y Wong
Journal:  Am J Hematol       Date:  2016-11-04       Impact factor: 10.047

9.  Erythrocyte adenosine deaminase: diagnostic value for Diamond-Blackfan anaemia.

Authors:  John H Fargo; Christian P Kratz; Neelam Giri; Sharon A Savage; Carolyn Wong; Karen Backer; Blanche P Alter; Bertil Glader
Journal:  Br J Haematol       Date:  2012-12-17       Impact factor: 6.998

10.  Danazol Treatment for Telomere Diseases.

Authors:  Danielle M Townsley; Bogdan Dumitriu; Delong Liu; Angélique Biancotto; Barbara Weinstein; Christina Chen; Nathan Hardy; Andrew D Mihalek; Shilpa Lingala; Yun Ju Kim; Jianhua Yao; Elizabeth Jones; Bernadette R Gochuico; Theo Heller; Colin O Wu; Rodrigo T Calado; Phillip Scheinberg; Neal S Young
Journal:  N Engl J Med       Date:  2016-05-19       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.